M Lopez, J Fechtenbaum, B David, C Martinache, M Chokri, S Canepa, A De Gramont, C Louvet, I Gorin, O Mortel
{"title":"Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study.","authors":"M Lopez, J Fechtenbaum, B David, C Martinache, M Chokri, S Canepa, A De Gramont, C Louvet, I Gorin, O Mortel","doi":"10.1097/00002371-199204000-00008","DOIUrl":null,"url":null,"abstract":"<p><p>Ninety-three collections of leucocytes by cytapheresis followed by separation of monocytes by centrifugal elutriation were undertaken in twelve metastatic cancer patients (four melanomas, six colon carcinomas, one ovarian carcinoma, and one lung cancer). The leucaphereses were performed aiming to collect a product, ready for introduction into the elutriation chamber, i.e., with low contamination by erythrocytes and granulocytes. The median collection of leucocytes was 7.3 x 10(9). After elutriation, purified monocytes (mean: 0.91 x 10(9)) were cultured with 3-5% autologous serum for 7 days in the presence of 250 IU/ml of recombinant human gamma-interferon (Rh-IFN gamma) for the last 18 h of culture. The median number of activated macrophages (MAK) available for reinfusion was 2.4 x 10(8) for each culture. The phenotypes and the antitumoral potentiality of MAK cells were documented. Reinfusions performed i.v. or i.p. were well tolerated with no major side effects. No complete tumor response was obtained. One partial response and two stabilizations of the disease were observed in one melanoma and two colon carcinomas.</p>","PeriodicalId":77209,"journal":{"name":"Journal of immunotherapy : official journal of the Society for Biological Therapy","volume":"11 3","pages":"209-17"},"PeriodicalIF":0.0000,"publicationDate":"1992-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00002371-199204000-00008","citationCount":"54","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunotherapy : official journal of the Society for Biological Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00002371-199204000-00008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 54
Abstract
Ninety-three collections of leucocytes by cytapheresis followed by separation of monocytes by centrifugal elutriation were undertaken in twelve metastatic cancer patients (four melanomas, six colon carcinomas, one ovarian carcinoma, and one lung cancer). The leucaphereses were performed aiming to collect a product, ready for introduction into the elutriation chamber, i.e., with low contamination by erythrocytes and granulocytes. The median collection of leucocytes was 7.3 x 10(9). After elutriation, purified monocytes (mean: 0.91 x 10(9)) were cultured with 3-5% autologous serum for 7 days in the presence of 250 IU/ml of recombinant human gamma-interferon (Rh-IFN gamma) for the last 18 h of culture. The median number of activated macrophages (MAK) available for reinfusion was 2.4 x 10(8) for each culture. The phenotypes and the antitumoral potentiality of MAK cells were documented. Reinfusions performed i.v. or i.p. were well tolerated with no major side effects. No complete tumor response was obtained. One partial response and two stabilizations of the disease were observed in one melanoma and two colon carcinomas.
我们对12例转移性癌症患者(4例黑色素瘤、6例结肠癌、1例卵巢癌和1例肺癌)进行了93例白细胞分离和单核细胞离心洗脱。白细胞的目的是收集一个产品,准备引入洗脱室,即低污染的红细胞和粒细胞。白细胞的中位数为7.3 x 10(9)。洗脱后,纯化的单核细胞(平均:0.91 × 10(9))与3-5%的自体血清在250 IU/ml重组人γ -干扰素(Rh-IFN γ)存在下培养7天,最后18小时培养。每次培养可用于回输的活化巨噬细胞(MAK)的中位数为2.4 x 10(8)。记录了MAK细胞的表型和抗肿瘤潜能。静脉或ip再输注耐受良好,无主要副作用。未获得完全的肿瘤反应。在一个黑色素瘤和两个结肠癌中观察到一个部分反应和两个稳定的疾病。